An epidemic of invasive fungal infection in a stem cell transplant unit; response to high-dose liposomal amphotericin B

Hematology Journal

Volumn 5, Issue 6, 2004, Pages 548-551

  Ryan, Clodagh ^a   McNicholsan, Siobhan ^a   O'Connell, Brian ^a   Forde, Stephanie ^a   Keoghan, Mary ^a   McCann, Shaun R ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CYCLOSPORIN; FLUCONAZOLE; STEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA; CANDIDA SEPTICAEMIA; CHILL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EPIDEMIC; FEBRILE NEUTROPENIA; HUMAN; MYCOSIS; NONHODGKIN LYMPHOMA; RIGOR; STEM CELL TRANSPLANTATION; THORAX RADIOGRAPHY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CROSS INFECTION; DISEASE OUTBREAKS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HOSPITAL UNITS; HUMANS; IRELAND; LIPOSOMES; MYCOSES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 11044238454     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200546     Document Type: Article

References (16)

1. Wald A, Leisenring W, Van Burik JA, Bowden RA. Epidemiology of Aspergillus infection in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
2. Lin MT, Lu HC, Chen W. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 2001; 33: 1621-1627.
3. Prentice GH, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D et al. A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-718.
4. McCann S, Byrne JL, Rovira M, Shaw P, Ribaud P, Sica S et al. Outbreaks of infectious diseases in stem cell transplant units; a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 2004; 33: 519-529.
5. Blum U, Windfuhr M, Buitrago-Tellez C, Sigmund G, Herbst EW, Langer M. Invasive pulmonary aspergillosis: MRI, CT and plain radiographic findings and their contribution to early diagnosis. Chest 1994; 106: 1156-1161.
6. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-1906.
7. Hospenthal, DR, Kwon-Chung KJ, Bennet JE. Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 1998; 36: 165-168.
8. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors and predictors of mortality. Clin Infect Dis 1992; 15: 414-421.
9. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-147.
10. Denning D, Kibbler CC, Barnes R. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-240.
11. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Croakaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
12. Ferns RB, Fletcher H, Bradley S, MacKinnon S, Hunt C, Tedder RS. The prospective evaluation of a nested polymerase chain reaction assay for the early detection of Aspergillus infection in patients with leukaemia or undergoing allograft treatment. Br J Haematol 2002; 119: 720-725.
13. Leenders A, Daenen R, Jansen W, Hop B, Lowenberg P, Wijermens J et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia associated invasive fungal infections. Br J Haematol 1998; 103: 205-212.
14. Walsh TJ, Pappas P, Winsyon DJ, Lazarus HM, Petersen F, Raffalli L et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
15. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell D, Roden M et al. Safety, tolerance and pharmacokinetics of high dose liposomal amphotericin B (Ambisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 12: 3487-3496.
16. Prentice GH, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-284.